RNAi Technologies Market Size, Share, Growth, And Industry Analysis, By Type (Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Other), By Application (Research, Therapeutics), Regional Insights and Forecast From 2025 To 2033

• 

   Request a Free Sample To Get More Information on this Market

RNAI TECHNOLOGIES MARKET REPORT OVERVIEW

The global rnai technologies market size stood at USD 0.36 billion in 2024 and is projected to reach USD 0.38 billion in 2025, growing further to USD 0.53 billion by 2033 at an estimated CAGR of 4.8% from 2025 to 2033.

A universal biological response to double-stranded RNA, known as RNA interference (RNAi) / post-transcriptional gene silencing (PTGS), promotes resistance to both endogenous parasite and foreign harmful nucleic acids and controls the expression of protein-coding genes. Sequence-specific gene silencing is a natural process that has the potential to transform experimental biology and have major uses in functional genomics, medical treatment, agriculture, and other fields.

RNAI TECHNOLOGIES MARKET KEY FINDING

• Market Size and Growth: Global rnai technologies market size stood at USD 0.36 billion in 2024 and is projected to reach USD 0.38 billion in 2025, growing further to USD 0.53 billion by 2033 at an estimated CAGR of 4.8% from 2025 to 2033.

• Key Market Driver: Chronic non-communicable diseases accounted for 75% of global deaths in 2022, fuelling demand for targeted RNAi therapies.

• Major Market Restraint: First-year treatment cost for lumasiran reaches USD 1.64 million per patient, reflecting high development and manufacturing expenses.

• Emerging Trends: By 2023, 79% of published RNAi clinical trials employed naked delivery, with GalNAc conjugation used in 77% to enhance hepatocyte targeting.

• Regional Leadership: North America held 35.8% of the global RNAi technology market share in 2023, supported by robust R&D infrastructure.

• Competitive Landscape: Alnylam Pharmaceuticals developed four of the six FDA-approved RNAi therapeutics as of 2024, underscoring its market leadership.

• Market Segmentation: The therapeutics segment represented approximately 38.2% of the RNAi technology market in 2023, led by oncology and liver disease applications.

• Recent Development: On May 14, 2024, Codexis announced the enzymatic synthesis of an siRNA oligonucleotide, advancing RNA-based therapeutic manufacturing.

COVID-19 IMPACT

"Potential Advantages of the Technology to Advance Market Growth"

The eruption ofCOVID-19has done act as a substantial restraint on some marketin 2020, as businesses have been disrupted due to global government lockdowns. COVID-19 is a contagious disease that causes flu-like symptoms such as fever, coughing, and difficulty breathing. The market's growth wassignificantly advanced by COVID-19 pandemic. As more effective COVID-19 disease therapies weredeveloped, themarketgradually advanced.

The article "Prospects for RNAi treatment of COVID-19" published in July 2020 states that RNAi contrary to COVID-19 disease may be instructed against a pair of distinct types of targets, including viral proteins necessary for SARS-CoV-2's survival and replication and host factors that regulate the virus's entry into and movement through cells. The potential advantages of RNAi technologies that enabled the research and development of COVID-19 treatment fueled the market expansion.

LATEST TRENDS

"Increased Collaborative Efforts to Intensify Market Magnification "

The market for RNAi technologies is expanding as a result of increased collaborative efforts between drug distribution corporations and contracted research organizations (CROs). ARO-XDH is an includes innovative RNA interference, RNAi, that Arrowhead Pharmaceuticals Inc. is developing as a potential therapy for people with unregulated gout.

On June 21, 2021, Arrowhead Pharmaceuticals Inc. along with Horizon Therapeutics plc stated an international partnership and license agreement for ARO-XDH. This partnership with Horizon also signifies an expansion of the rapidly expanding portfolio of investigational RNAi treatments offered by Arrowhead Pharmaceuticals, which are based on its patented Targeted RNAi Molecules (TRiMTM) technology. Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) and GSK Pharmaceuticals started a Phase-I research of ISIS-HBV-L Rx in January 2016. This purchase seeks to treat viral hepatitis B infection.

• According to the U.S. National Center for Biotechnology Information (NCBI) Bookshelf, the U.S. Food and Drug Administration has approved 6 small interfering RNA (siRNA) therapeutics—patisiran, givosiran, lumasiran, inclisiran, nedosiran and vutisiran—marking a rapid expansion in clinical translation of RNA interference technologies.

• Data from NIH RePORTER show that at least 11 separate NIH grants are currently funding RNAi- and antisense-based drug research, underscoring growing federal support for RNAi pipeline development.

RNAI TECHNOLOGIES MARKET SEGMENTATION

By Type

According to type, the market can be segmented into oncology, ocular disorders, respiratory disorders, liver diseases, others.

Oncology is the leading part of the type segment.

By Application

According to application, the market can be segmented into research, therapeutics.

Research is the leading part of the application segment.

DRIVING FACTORS

"Pharmaceutical Firms to Boost Market Share "

Long-term RNAi-based medicines have a bright future ahead of them, as does any clinical trial with them. Therapeutics based on RNA interference (RNAi) have an opportunity to treat a wide range of ailments, as well as uncommon and hereditary disorders. As a result, biotech and pharmaceutical firms are spending a lot of money developing RNAi therapeutics, and this pattern is anticipated to last throughout the projected period. This should help the market flourish as a result.

Due to favorable government programs and policies, the accessibility of sustainable funding for research, and a sizable infrastructure for development and research, RNA-based therapeutics research is expanding globally, but especially in North America. Throughout the forecast period, it is anticipated that this trend will persist, fueling RNAi technologies market share expansion.

"Growth in Chronic Disease to Expand Market Forwarding"

Over the course of the forecast period, it is anticipated that the prevalence of chronic diseases such as cancer, diabetes, cardiovascular disease, TB, AIDS, and more will increase globally. Therapeutics based on RNA have the potential to treat a wide range of chronic illnesses as well as uncommon and hereditary abnormalities. According to data fromWorld Health Organization, tumor, chronic respiratory conditions, and diabetes are the leading causes of NCD (Non-Communicable Disease) fatalities, each year accounting for 17.9 million individuals.

Over the forecast period, more RNAi therapies or treatments are anticipated to be approved, which is anticipated to boost RNAi technologies market growth.

• The National Institutes of Health allocated $264 million to 535 RNAi- and antisense-based clinical research projects, representing 2% of the NIH’s total extramural clinical research budget in FY 2020—demonstrating substantial public-sector backing.

• Patisiran (Onpattro) alone received 4 FDA expedited designations—Orphan Drug (June 14, 2012), Fast Track (October 31, 2013), Breakthrough Therapy (November 12, 2017) and Priority Review (February 1, 2018)—highlighting strong regulatory support for RNAi therapeutics.

RESTRAINING FACTORS

"Strict Rules and Regulations to Deplete Market Advancement "

The development of the global RNAi technologies market is anticipated to be hampered by the stable, possibly immunogenic nature of RNA. For example, RNA often needs a means of delivery vehicle for effective transport to the cells of interest because it is intrinsically unstable, potentially immunogenic, and potentially immunogenic. Additionally, due to its immunogenicity and labile nature, mRNA is not suitable for clinical use in its current form. In consequence, it is anticipated that this will impede RNAi technologies market expansion.

The market for RNAi technologies is anticipated to experience growing challenges due to strict rules and regulations.

• In a pooled safety analysis of 143 participants receiving the investigational siRNA nedosiran, instances of severe thrombocytopenia (platelet count ≤ 100,000 cells/µL) were reported, underscoring delivery and safety hurdles in RNAi therapy development.

• According to recent HHS grant termination data, the CDC-NU2GGH002503 grant of $186,000 intended for HIV laboratory integration services was terminated on March 24, 2025, illustrating potential funding discontinuities that can delay RNAi research programs.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market

RNAI TECHNOLOGIES MARKET REGIONAL INSIGHTS

"Requirement of Cutting-Edge Technologies to Uplift Market Growth in North America "

Due to the increasing prevalence of the target diseases and the growing need for cutting-edge medicines and diagnostics, North America is predicted to offer profitable potential for the market's expansion. For instance, nearly 1.9 million new instances of cancer are anticipated to be identified in the regionin 2022, according to a forecast by the American Cancer Society. Moreover, 57% of cancer patients in the regionare65 or older, and 80% of those with cancer are older than 55. As a result, the need for tests and therapies is strong in the nation due to a high incidence of cancer and the growing number of geriatric patients, which is likely to fuel expansion in the market.

KEY INDUSTRY PLAYERS

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

The analyst provides a comprehensive picture of the market through the study, synthesis, and summarization of data from various sources, as well as an examination of important variables such as financial gain, sales prices, competition, and promotions. It identifies the key industry influencers and presents various market facets. The information provided is thorough, reliable, and the result of extensive primary and secondary research. Themarket report provides a comprehensive competitive landscape as well as an in-depth vendor evaluation methodology and analysis based on both qualitative and quantitative studies to accurately forecast market growth.

The reports cover important advances with in market, as well as inorganic and organic growth strategies. Various companies are concentrating on organic business expansion such as product announcements, product approvals, and other things like patents and events. Acquisitions, partnerships, and collaborations were among the inorganic growth strategies observed in the market. The above activities have paved the way for market participants to expand their business and customer base. With the growing demands for filter products in the international market, market participants in the market areexpected to benefit from substantial growth opportunities in the near future.

• Alnylam Pharmaceuticals (U.S.): Alnylam has secured FDA approval for 4 of the 6 siRNA agents (patisiran, givosiran, lumasiran, vutisiran), making it the leading developer in the RNAi space.

• Benitec Biopharma Ltd (Australia): According to ClinicalTrials.gov, Benitec Biopharma Ltd is listed as the sponsor for 1 active interventional study evaluating an RNAi therapeutic candidate, marking its entry into clinical-stage development.

List of Top Rnai Technologies Companies

• Alnylam Pharmaceuticals (U.S.)
• Benitec Biopharma Ltd (Australia)
• Filmtec Corporation (U.S.)
• Ionis Pharmaceuticals (U.S.)
• Quark Pharmaceuticals Inc. (Israel)
• RXI Pharmaceuticals (U.S.)
• Qiagen (Germany)
• Invitrogen (U.S.)
• Ambion (U.S.)

REPORT COVERAGE

The industry's growth was significantly influenced by the tactics employed by market participants in recent years, such as extensions. The report provides details and information on the companies and their interactions with the market. The data is gathered and published through appropriate research, technological advancements, expansions, and expanding machinery and equipment. Other criteria considered for this market are the firms that develop and provide new products, the areas in which they operate, mechanisation, innovative techniques, making the most money, and using their products to have a large social impact. This analysis examines the global and regional effects of the outbreak mostly on the market. The study describes the market share features, and market growth by type, industry, and customer sector.

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.